DISCOVER SYLENTIS
Media
If you need to contact our communication department, please do it by contacting:
- Lara Vadillo Muñoz
- Miriam Collados Gordo
- Pharma Mar Communication Dept.
- Phone: +34 91 846 6000
Press releases
Sylentis, a PharmaMar Group company, announces the positive results of the Phase IIa dose-ranging study for SYL1801 in patients with Age-Related Macular Degeneration (AMD)
The primary endpoint was reached, a mean gain from baseline was observed in a middle [...]
Sylentis, a PharmaMar Group company, announces the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint
FYDES achieved the primary endpoint of the study by demonstrating the long-term safety of tivanisiran [...]
18
Dec
Dec
Sylentis, a PharmaMar Group company, begins a new Phase II trial with SYL1801 for patients with Age-Related Macular Degeneration
Madrid, November 23rd, 2022. – Sylentis, a PharmaMar Group Company (MSE:PHM), has announced today the [...]
23
Nov
Nov
Sylentis, a wholly owned subsidiary of PharmaMar, inaugurates first oligonucleotide manufacturing plant in Spain
The plant, which has a surface area of 400m2, will serve both Sylentis’ manufacturing needs [...]
19
Apr
Apr
Sylentis initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease
This Phase III study, called FYDES, will involve 26 hospitals in the United States. It [...]
01
Apr
Apr
Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases
This trial involved 36 healthy volunteers who were administered eye drops for the treatment and/or [...]
14
Mar
Mar
Sylentis, PharmaMar Group, initiates a Phase I clinical trial with SYL1801 for retinal diseases
This Phase I trial will enroll 36 healthy volunteers and will be conducted at the [...]
18
Mar
Mar
Sylentis, a PharmaMar Group company, appoints Andreas Segerros as Chief Executive Officer
Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has appointed Andreas Segerros as Chief Executive Officer (CEO). This new appointment aims to redirect Sylentis’ strategic direction with an independent management from PharmarMar. Andreas brings a wealth of [...]
Sylentis, a PharmaMar Group Company, to present new data at ARVO 2023
Sylentis, a PharmaMar Group Company (MSE:PHM), has announced today that it is presenting at ARVO 2023 advances on two of its ophthalmic studies based on RNA interference (RNAi) technology: Tivanisiran, for Dry Eye Disease (DED); and SYL1801, [...]
FDA authorizes Sylentis (PharmaMar Group) to initiate Phase III trial with tivanisiran for the treatment of dry eye disease
This Phase III study, called SYL1001_V, will involve more than 30 hospitals in the United States. It will evaluate the efficacy and safety of tivanisiran ophthalmic solution on the signs and symptoms of patients with dry eye [...]
Sylentis (PharmaMar Group) at ARVO 2019 with results from two ophthalmic drugs: tivanisirán and SYL1801
The company will present results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome, in which an improvement in central corneal damage and results in patients with Sjögren’s Syndrome are demonstrated. Sylentis [...]
Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease
The HELIX trial has shown improvement (p=0.035) in the reduction of central corneal staining Data will be presented to the FDA and other regulatory authorities during the second quarter of 2019 to define the regulatory strategy The [...]
Sylentis, PharmaMar Group, announces the end of patient recruitment for its HELIX trial
Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease. We estimate that the results of the trial will be available [...]
Sylentis announces new data on the treatment of allergic conjunctivitis
The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its [...]
Sylentis presented new results for the treatment of age associated macular degeneration
Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization . Madrid, 4th of May, 2018. Within the framework of the annual [...]
Sylentis announces the clinical results of tivanisiran for the treatment of dry eye syndrome
The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome Madrid, May 3rd, 2018. Sylentis, Pharmaceutical Company [...]
Español